Future multibillion-dollar obesity market will be dominated by Novo and Lilly, bank predicts

Players are beginning to position themselves as a very lucrative market for weight-loss drugs matures, but Morgan Stanley believes the two rivals Novo Nordisk and Eli Lilly will take almost half.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
by marketwire, translated by daniel pedersen

Eli Lilly, Amgen, and a number of other companies are seeking to challenge Novo Nordisk on the obesity market, which is facing a demand boom in coming years, investment bank Morgan Stanley assesses according to media Financial Times.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading

Foto: MedWatch

Top news from MedWatch this week